Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Nobel-winning therapy weaponises immune system against cancer

Nobel-winning therapy weaponises immune system against cancer

While chemotherapy destroys cancerous cells along with normal cells, often with toxic and debilitating effects on a patients’ body, immunotherapy unleashes the body’s immune system to target tumour cells

A revolutionary cancer treatment pioneered by the winners of the 2018 Nobel Prize for Medicine has been hailed as the future of fighting the disease—and it has fewer devastating side effects than chemotherapy.

While chemotherapy destroys cancerous cells along with normal cells—often with toxic and debilitating effects on a patient—immunotherapy unleashes the body’s immune system to target tumour cells.

James Allison of the US and Tasuku Honjo of Japan won the Nobel on Monday for identifying two different brakes on the immune system which, when turned off, allow the body’s defence system to attack cancerous cells faster and more effectively.

Allison was one of two scientists to discover the blocking effect for one such brake—or checkpoint inhibitor molecule—called CTLA-4 in 1995. Honjo discovered another, PD-1, around the same time.

Once these brakes were identified, researchers were able to work on how to turn them off and get T-cells—white blood cells—to start attacking.

“The goal is to neutralise these molecules, among them CTLA-4 and PD-1, and these are what the recipients of the Nobel prize have been working on,” said Pierre Golstein, emeritus professor at the Marseille-Luminy Immunology Centre.

“We neutralise these and the white blood cells can get to work on the cancer cells,” he added.

Sheena Cruickshank, an immunology lecturer at the University of Manchester in Britain, said the therapy has “enabled us to harness the power of the body to help heal itself”.

“A lot of conventional cancer therapies are about destroying cells and can be quite damaging, but this is much more targeted and much more specific because it’s enabling our immune cells to come in and actually kill the tumour cells directly,” she told AFP.

Booming field

The therapy has only been used on patients for a few years, and is less effective for certain cancers such as pancreatic and brain cancer.

But 800 clinical trials were in progress worldwide and more than 30 drugs under development as of June, according to the American Cancer Society.

And the pharmaceutical industry has heavily invested in research in the field.

The US Food and Drug Administration has already approved a number of immunotherapy treatments, including some targeting PD-1.

“The booming field of immunotherapy that these discoveries have precipitated is still relatively in its infancy, so it’s exciting to consider how this research will progress in the future,” said Charles Swanton, Cancer Research UK’s chief clinician.

Goldstein, whose team first identified the CTLA-4 molecule in 1987, said the results have been very promising.

“Immunotherapy is now possibly the most important recent discovery for cancer therapy in general, as an alternative to chemo,” he said.

“For example, immunotherapy can control between 20 and 50 percent of certain advanced melanomas, which is something considering that situation would have been a death sentence not too long ago.”

But it’s also not totally harmless, he added.

“Activated immune cells can cause certain auto-immune complications in certain organs, but we can control those,” he said.

A study released in June tested a form of immunotherapy against chemo for non-small-cell lung cancer, the most common lung cancer worldwide.

It found that the drug Keytruda (pembrolizumab)—which famously helped former US president Jimmy Carter stave off advanced melanoma that had spread to his brain—helped lung cancer patients live four to eight months longer than chemo.

Not for all cancers

However, Karl Peggs of the University College of London said the therapy is not for everyone.

“We know that some patients have a very low chance of responding… those with little evidence that these pathways are actively restricting the immune system, or those with cancers that are less heavily mutated,” he said.

While in theory it should work for most forms of cancer, it’s most effective on those with the highest numbers of mutations such as melanomas, lung cancer and smoking, he added.

And it has sometimes been met with too much enthusiasm by patients. In the US, some have reportedly asked their doctors to immediately use immunotherapy instead of traditional treatments like chemotherapy, even when they are more effective.

After his big win on Monday, Allison warned that immunotherapy will not replace all other cancer treatments.

Instead, it is “going to be part of therapy that potentially all cancer patients will receive in five years,” he told a press conference in New York.

Honjo, meanwhile, said he wanted to continue his research “so that this immune therapy will save more cancer patients than ever”.


Explore further:
US, Japan duo win Nobel Medicine Prize for cancer therapy

Tagged with:

About author

Related Articles